COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,625 Articles (22,913 medRxiv, 8,712 bioRxiv)

Most recent first Previous |  Page 953: Articles 9521-9530  | Next

Quantifying the effect of isolation and negative certification on COVID-19 transmission
Takeshita, J.-i., Murakami, M., Kamo, M., Naito, W., Yasutaka, T., Imoto, S.
10.1101/2022.02.20.22270449 — Posted: 2022-02-22
Persisting pulmonary dysfunction in pediatric post-acute Covid-19
Heiss, R., Wagner, A. L., Tan, L., Schmidt, S., Regensburger, A. P., Ewert, F., Mammadova, D., Buehler, A., Vogel-Claussen, J., Voskrebenzev, A., Rompel, O., Nagel, A. M., Levy, S., Bickelhaupt, S., May, M. S., Uder, M., Metzler, M., Trollmann, R., Woelfle, J., Knieling, F.
10.1101/2022.02.21.22270909 — Posted: 2022-02-22
COVID-19 vaccine incentive scheduling using an optimally controlled reinforcement learning model
Stuckey, K., Newton, P.
10.1101/2022.02.17.22271145 — Posted: 2022-02-22
SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway
Sarjomaa, M., Diep, L. M., Zhang, C., Tveten, Y., Reiso, H., Thilesen, C., Nordbo, S. A., Berg, K. K., Aaberge, I., Pearce, N., Kersten, H., Vandenbroucke, J. P., Eikeland, R., Fell, A. K. M.
10.1101/2022.02.16.22271075 — Posted: 2022-02-21
At least three doses of leading vaccines essential for neutralization of SARS-CoV-2 Omicron variant
Singanallur, N. B., Jansen van Vuren, P., McAuley, A. J., Bruce, M. P., Kuiper, M. J., Gwini, S., Riddell, S., Goldie, S., Drew, T. W., Blasdell, K. R., Tachedjian, M., Mangalaganesh, S., Chahal, S., Caly, L., Druce, J. D., Juno, J. A., Kent, S., Wheatley, A. K., Vasan, S. S.
10.1101/2022.02.20.22271237 — Posted: 2022-02-21
Four doses of the inactivated SARS-CoV-2 vaccine redistribute humoral immune responses away from the Receptor Binding Domain
Wang, J., Deng, C., Liu, M., Liu, Y., Li, L., Huang, Z., Shang, L., Jiang, J., Li, Y., Mo, R., Zhang, H., Liu, M., Peng, S., Xiao, H.
10.1101/2022.02.19.22271215 — Posted: 2022-02-21
Wastewater surveillance using ddPCR reveals highly accurate tracking of omicron variant due to altered N1 probe binding efficiency
Schussman, M. K., Roguet, A., Schmoldt, A., Dinan, B., McLellan, S. L.
10.1101/2022.02.18.22271188 — Posted: 2022-02-21
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial
ADER, F., PEIFFER-SMADJA, N., POISSY, J., BOUSCAMBERT-DUCHAMP, M., BELHADI, D., DIALLO, A., DELMAS, C., SAILLARD, J., DECHANET, A., MERCIER, N., DUPONT, A., ALFAIATE, T., LESCURE, F.-X., RAFFI, F., GOEHRINGER, F., KIMMOUN, A., JAUREGUIBERRY, S., REIGNIER, J., NSEIR, S., DANION, F., CLERE-JEHL, R., BOUILLER, K., NAVELLOU, J.-C., TOLSMA, V., CABIE, A., DUBOST, C., COURJON, J., LEROY, S., MOOTIEN, J., GACI, R., MOURVILLIER, B., FAURE, E., POURCHER, V., GALLIEN, S., LAUNAY, O., LACOMBE, K., LANOIX, J.-P., MAKINSON, A., MARTIN-BLONDEL, G., BOUADMA, L., BOTELHO-NEVERS, e., GAGNEUX-BRUNON, A., EPAULARD, O., PIROTH, L., WALLET, F., RICHARD, J.-C., REUTER, J., STAUB, T., LINA, B., NORET, M., ANDREJAK, C., LE, M.-P., PEYTAVIN, G., HITES, M., COSTAGLIOLA, D., YAZDANPANAH, Y., BURDET, C., MENTRE, F., DisCoVeRy study group
10.1101/2022.02.16.22271064 — Posted: 2022-02-21
Genomic monitoring unveils a high prevalence of SARS-CoV 2 Omicron Variant in vaccine breakthrough cases in Bahia, Brazil
Campos, G. S., Giovanetti, M., de Moraes, L., da Hora, H. S., Alcantara, K. M., Sardi, S. I.
10.1101/2022.02.16.22271059 — Posted: 2022-02-21
Insights on Telemedicine Use by Physiatrists Before, During, and Beyond the COVID-19 Pandemic
Sobrepera, M. J., Weseloh, A., Chaudhri, D., Johnson, M. J.
10.1101/2022.02.19.22270722 — Posted: 2022-02-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).